The Children's Hospital of Pennsylvania

The Children's Hospital of Philadelphia (CHOP) is a world-renowned pediatric healthcare institution and research powerhouse founded in 1855. As the first hospital in the United States dedicated exclusively to children, it has evolved into a global leader in medical innovation, particularly in the fields of cell and gene therapy. CHOP's Research Institute is credited with the foundational development of landmark treatments, including the first FDA-approved CAR-T cell therapy, Kymriah, and the first gene therapy for an inherited disease, Luxturna. The organization operates a massive clinical network and maintains one of the largest pediatric research programs in the world, consistently ranking among the top recipients of NIH funding. CHOP serves as a critical hub for pediatric clinical trials and academic collaboration, bridging the gap between laboratory discovery and bedside care.